ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
September 19, 2024 05:22 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry...
Radiopharmaceuticals Market Size to Achieve USD 13.67 Billion by 2033
September 12, 2024 11:00 ET
|
Precedence Research
Ottawa, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market size is predicted to increase from USD 5.97 billion in 2023 to approximately USD 13.67 billion by 2033, According to...
Transforming Cancer Care: Novotech Releases Report on Radiopharmaceuticals Global Clinical Trials Landscape
June 26, 2024 16:41 ET
|
Novotech
Transforming Cancer Care: Novotech Releases Report on Radiopharmaceuticals Global Clinical Trials Landscape
ITM ernennt Dr. Andrew Cavey zum CEO, um das weitere Wachstum des Unternehmens voranzutreiben
June 20, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Dr. Cavey verfügt über langjährige Berufserfahrung in der radiopharmazeutischen Industrie und wird die Weiterentwicklung von ITMs Pipeline und das Unternehmenswachstum maßgeblich unterstützen....
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
June 20, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s pipeline and business growth Garching /...
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
June 06, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...
Lantheus Announces Executive Appointments to Accelerate Innovation
May 15, 2024 16:30 ET
|
Lantheus Holdings, Inc.
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”)...
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
May 07, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline...
ITM Obtains Manufacturing License in the U.S.
February 01, 2024 07:00 ET
|
ITM Isotope Technologies Munich SE
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and...
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
January 16, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...